Navigation Links
Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer
Date:10/2/2007

SANTA FE, N.M., Oct. 2 /PRNewswire-FirstCall/ -- John Cousins, President of Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, testified Monday before the New Mexico State Legislature's Interim Tobacco Settlement Committee in support of the lawmakers' $1.3 million proposal for funding a clinical study using the company's assay for early lung cancer detection.

The New Mexico legislature last year appropriated $350,000 to fund a clinical study that will begin later this year to screen veterans for lung cancer at its earliest stages. If approved, the $1.3 million funding proposal for 2008 would be a continuation of existing funding for the clinical study and will be considered during the state's 30-day legislative session beginning January 15, 2008.

"Members of the Tobacco Settlement Committee are at the forefront of funding essential studies to develop a nationwide screening protocol for lung cancer that ultimately will result in saving millions of lives," said Cousins. "We look forward to being part of this breakthrough effort and we are thrilled to be helping our veterans in this process. The men and women who served our country deserve the very best healthcare. This clinical work will provide just that."

Doug Craft, President of the Black Veterans Association of New Mexico, testified in support of Biomoda's efforts. "We are grateful for this opportunity and plan to work very hard to let our brothers and sisters who served in the military learn about, and be part of, this important opportunity that not only will further essential research, but also save lives."

Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins (505) 821-0875


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Clintons new problem - Is the outgoing American president suffering from skin cancer?
2. Past President Narayanans Condition Still Critical
3. President and Founder of National Obesity Forum Resigns
4. President Bush Urges Citizens to Invest In Health Savings Account (HSAs)
5. President Bush proposes HSAs scheme for the benefit of both the workers and the country
6. President’s verdict: no need to panic over bird fl
7. Delhi Hospitals On Standby For President Bush
8. Former IMO President Shows Interest In Winning General Election
9. Chicken Dishes Were Off The Menu At Pakistan Presidents House
10. Man Appeals to President to Save His Ailing Son
11. President Kalam Meets Striking Medicos However Stir to Continue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 20, 2017 , ... ... in which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... to remote participants for real-time collaboration and immediate decision-making requirements. While never ...
(Date:7/20/2017)... ... 2017 , ... Vixiar Medical, Inc. , a privately ... monitoring cardiopulmonary diseases, announced today that it has raised seed round financing of ... fund final engineering and initial production of the Company’s first product, Indicor™, a ...
(Date:7/20/2017)... ROUGE, La. (PRWEB) , ... July 20, 2017 , ... ... to the staff. Dr. Dunbar received his BS in Biology from LSU, graduating summa ... the Medical School Class President. After his residency in St. Louis, Dr. Dunbar moved ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Business Architecture Guild® ... Knowledge (BIZBOK® Guide )v 6.0 is now available for member download. This release ... collaborative teams. , Non-members may download the Part 1 Introduction for free ...
(Date:7/20/2017)... NC (PRWEB) , ... July 20, 2017 , ... LINET, ... the latest innovation to their product line: the AVE 2 birthing bed. , Perfectly ... helps bring a new level of comfort and efficiency to every phase of childbirth. ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... , July 13, 2017 It should come as ... is in the midst of a crippling opioid ... since 1999, the number of overdose deaths from opiate-based medications ... over half a million dead from 2001 to 2015". During ... and hydrocodone has similarly quadrupled, drawing a compelling link between ...
(Date:7/13/2017)... , July 13, 2017  New York City-based market ... pharmaceutical markets should be aware of.  From new products to ... are detailed in a recently completed study, Potential Pipeline ... 1.  Age-Driven Growth - ... have been aware of the impact the growing population and, ...
(Date:7/11/2017)... July 11, 2017 Zymo Research Corp., also known as ,The ... quantify biological aging in a precise manner using the myDNAge ™ ... , a professor of human genetics and biostatistics at the David ... Public Health , Zymo Research,s proprietary DNAge ™ technology is used ... ...
Breaking Medicine Technology: